Who are Aricept® Evess's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bloxiverz, Razadyne, Camptosar, Camptosar, Zantac, Dyclone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aricept-evess.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Aricept® Evess — Competitive Intelligence Brief

Aricept® Evess (Aricept® Evess) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cholinesterase inhibitor. Area: Neurology.

phase 2 Cholinesterase inhibitor Acetylcholinesterase Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Aricept® Evess (Aricept® Evess) — Pfizer. Aricept Evess is a cholinesterase inhibitor that works by increasing the concentration of acetylcholine in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aricept® Evess TARGET	Aricept® Evess	Pfizer	phase 2	Cholinesterase inhibitor	Acetylcholinesterase
Bloxiverz	NEOSTIGMINE	Fresenius Kabi	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	marketed	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Camptosar	Irinotecan Hydrochloride	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Camptosar	onivyde	Pfizer	marketed	Topoisomerase Inhibitor	Acetylcholinesterase	1996-01-01
Zantac	ranitidine	GSK (originally Glaxo)	marketed	H2 receptor antagonist	Multidrug and toxin extrusion protein 1, Acetylcholinesterase, Histamine H2 receptor	1983-06-01
Dyclone	DYCLONINE		marketed	dyclonine	Acetylcholinesterase	1982-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-01-06 — Camptosar · 8329213 · US
2027-01-06 — Camptosar · 8329213 · Compound · US
2028-08-29 — Camptosar · 8147867 · Compound · US
2028-08-29 — Camptosar · 8147867 · US
2033-06-12 — Camptosar · 9364473 · US
2033-06-12 — Camptosar · 9452162 · US
2033-06-12 — Camptosar · 9492442 · US
2033-06-12 — Camptosar · 9717724 · US
2033-06-12 — Camptosar · 9717724 · Method of Use · US
2033-06-12 — Camptosar · 9364473 · Method of Use · US
2033-06-12 — Camptosar · 12364691 · Method of Use · US
2033-06-12 — Camptosar · 11369597 · Method of Use · US
2033-06-12 — Camptosar · 9339497 · Method of Use · US
2033-06-12 — Camptosar · 9452162 · Method of Use · US
2033-06-12 — Camptosar · 9492442 · Method of Use · US
2033-06-12 — Camptosar · 10980795 · US
2033-06-12 — Camptosar · 11369597 · US
2033-06-12 — Camptosar · 9339497 · US
2033-06-12 — Camptosar · 10980795 · Method of Use · US
2036-08-19 — Camptosar · 11344552 · Method of Use · US
2036-10-15 — Camptosar · 10456360 · US
2036-10-15 — Camptosar · 10993914 · US
2036-10-15 — Camptosar · 12059497 · Formulation · US
2036-10-15 — Camptosar · 10456360 · Formulation · US
2036-10-15 — Camptosar · 10993914 · Formulation · US

Sponsor landscape (Cholinesterase inhibitor class)

Novartis · 3 drugs in this class
Eisai Co., Ltd. · 1 drug in this class
Icure Pharmaceutical Inc. · 1 drug in this class
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
Pfizer · 1 drug in this class
Pontificia Universidade Catolica de Sao Paulo · 1 drug in this class
Singapore General Hospital · 1 drug in this class
Sunnybrook Health Sciences Centre · 1 drug in this class
Taipei Veterans General Hospital, Taiwan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aricept® Evess — Competitive Intelligence Brief. https://druglandscape.com/ci/aricept-evess. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab